Home | Sitemap | Search | Contact A- A A+
   
English
 
    Public Member Support us  
 
About IBCSG
Patients & Public
Health Professionals
Open Trials
IBCSG 22-00
IBCSG 23-01
IBCSG 24-02
IBCSG 25-02
IBCSG 27-02
IBCSG 34-05
IBCSG 35-07
IBCSG 36-07
IBCSG 37-07
Closed Trials
Tissue Bank / Translational Research
Home > Public > Health Professionals > Open Trials > IBCSG 25-02

IBCSG 25-02 / BIG 3-02 (TEXT) 

A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer

Tamoxifen and Exemestane Trial (TEXT)

DESIGN

please click on the picture to see a larger version
Study Chairs
BIG: Dr. Olivia Pagani - Mendrisio, Switzerland
US Intergroup: Dr. Barbara Walley - Calgary, Canada

Statistician
Dr. Meredith Regan

Trial Coordinators
Karolyn Scott, Jocelyn Swick, Chris Rickard, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg24-26_STP@fstrf.org

Date of Activation
August 4, 2003

Targeted Accrual
1845 patients
Other Pathology

News

11.12.2008:
BIG 1-98: Results from sequential treatment analysis and updated monotherapy analysis

11.12.2008:
Brinker Award for Richard Gelber and Aron Goldhirsch

11.12.2008:
All presentations from investigators' meetings at San Antonio Breast Cancer Symposium now

All News

  
  Print
Disclaimer | Copyright